Assessment of Adebelizumab Combined With Chemotherapy in Concurrent Radiotherapy Versus Sequential Radiotherapy as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer

Clinical trial NCT06768307 · RECRUITING

Trial details

NCT number: NCT06768307
Sponsor: Peking University Cancer Hospital & Institute
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

SCLC, Extensive Stage Immunotherapy Chemotherapy Radiotherapy

Start date: 2025-01-07
Primary completion: 2027-01-31
Enrollment: 60

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.